预约演示
更新于：2025-10-25
Vonoprazan Fumarate
富马酸伏诺拉生
更新于：2025-10-25
概要
基本信息
药物类型 小分子化药 |
别名 VONOPION、Vonoprazan、Vonoprazan fumarate (JAN/USAN) + [14] |
作用方式 阻滞剂 |
作用机制 H+/K+ ATPase阻滞剂(钾离子转运ATP酶复合体阻滞剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H20FN3O6S |
InChIKeyROGSHYHKHPCCJW-WLHGVMLRSA-N |
CAS号881681-01-2 |
关联
468
项与 富马酸伏诺拉生 相关的临床试验NCT06851559
A Phase 2, Randomized, Double-Blind, Multi-Center Study in Adult Subjects With Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Up to 24 Weeks
TCTR20250606002
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Vonoprazan Film-coated Tablet 20 mg relative to VOCINTI 20 MG (Vonoprazan Film-coated Tablet 20 mg) in healthy Thai volunteers under fasting condition
NCT07179159
Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial
100 项与 富马酸伏诺拉生 相关的临床结果
登录后查看更多信息
100 项与 富马酸伏诺拉生 相关的转化医学
登录后查看更多信息
100 项与 富马酸伏诺拉生 相关的专利（医药）
登录后查看更多信息
791
项与 富马酸伏诺拉生 相关的文献（医药）2025-11-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Delafloxacin and levofloxacin activities on Helicobacter pylori in Bulgaria over four years
Article
作者: Boyanova, Lyudmila ; Markovska, Rumyana ; Katsarov, Nikolay ; Gergova, Galina ; Gergova, Raina ; Boyanova, Liliya Yordanova ; Kandilarov, Nayden ; Kamburov, Victor ; Medeiros, José ; Hadzhiyski, Petyo
Delafloxacin is a potent 4th-generation fluoroquinolone with enhanced activity in acidic environments. However, recently, delafloxacin resistance in facultative anaerobic species has been reported. Thus, we examined levofloxacin and delafloxacin susceptibility of 98 Helicobacter pylori strains in 2020-2023. Minimum inhibitory concentrations (MICs) were detected with E tests. Levofloxacin resistance was 33.7%, while delafloxacin resistance was 2.0% at 1 mg/l (the levofloxacin resistance breakpoint for H. pylori), and 9.2% at 0.125 mg/l (the recently suggested delafloxacin ECOFF for the species). Overall proportion of the strains exhibiting >0.125 mg/l delafloxacin MICs was similar to that in the previous study in 2018-2019 (8.5%). None of the 65 levofloxacin susceptible strains had delafloxacin MICs of >0.125 mg/l. Among levofloxacin resistant strains, delafloxacin MICs >1 mg/l (6.1%, 2/33 strains) were detected only in 2022 and 2023. Briefly, the results showed the much higher activity of delafloxacin over levofloxacin. The high delafloxacin activity in acidic environments is an additional advantage of the newer fluoroquinolone for treating H. pylori infection. Given that fluoroquinolone-based eradication regimens can be used as a second- or third-line therapy for H. pylori, testing the susceptibility of levofloxacin-resistant strains to delafloxacin could provide a useful option for eradication of the frequent and potentially carcinogenic bacteria. New regimens, such as the combination of vonoprazan with delafloxacin and another antibiotic deserve investigation.
2025-10-17JOURNAL OF ORGANIC CHEMISTRY
Synthesis of Secondary N-Methylamines via Reductive Amination of Aldehydes with N-Boc-N-Methylamine Using Me2SiHCl
Article
作者: Kim, Tae Lyn ; Cheon, Cheol-Hong ; Jeong, Myunghoon
A novel protocol for the synthesis of secondary N-methylamines via reductive amination of aldehydes with N-Boc-N-methylamine has been developed, using Me2SiHCl as the reductant. The reaction proceeds through the formation of Boc-protected secondary N-methylamines, which undergo in situ Boc-deprotection facilitated by HCl generated during the initial reductive amination. This method features a broad substrate scope, efficiently accommodating a wide range of aldehydes and affording the desired secondary N-methylamines in excellent yields. Notably, the resulting N-methylamines are isolated as their HCl salts, which exhibit poor solubility in common organic solvents, enabling facile purification by simple filtration. The utility of this strategy was further demonstrated in the synthesis of vonoprazan, a marketed drug used to treat gastroduodenal ulcers and reflux esophagitis, where the N-methylamine moiety was introduced in the final step via the developed reductive amination.
2025-10-01JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Correction to “Vonoprazan is Superior to Lansoprazole for Healing of Severe but Not Mild Erosive Esophagitis: A Systematic Review With Meta‐Analysis of Randomized Controlled Trials”
100 项与 富马酸伏诺拉生 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非糜烂性胃食管反流病 | 美国 | 2024-07-17 | |
| 糜烂性食管炎 | 美国 | 2023-11-01 | |
| 胃灼热 | 美国 | 2023-11-01 | |
| 糜烂性胃食管反流病 | 韩国 | 2019-03-29 | |
| 十二指肠溃疡 | 日本 | 2014-12-26 | |
| 反流性食管炎 | 日本 | 2014-12-26 | |
| 幽门螺杆菌感染 | 日本 | 2014-12-26 | |
| 胃溃疡 | 日本 | 2014-12-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性反流病 | 临床3期 | 美国 | 2022-01-17 | |
| 嗜酸粒细胞性食管炎 | 临床2期 | 美国 | 2025-12-01 | |
| 消化性溃疡出血 | 临床2期 | - | 2025-02-01 | |
| 胃食管反流 | 临床2期 | 比利时 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 保加利亚 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 捷克 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 爱沙尼亚 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 波兰 | 2016-07-14 | |
| 胃食管反流 | 临床2期 | 英国 | 2016-07-14 | |
| 消化不良 | 临床1期 | 中国 | 2024-05-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 幽门螺杆菌感染 一线 | 121 | 艱製鹽鹹鏇壓淵顧築構(壓鬱積築艱廠鹽壓壓壓) = 齋鬱窪憲顧鬱艱衊鑰觸 廠網網積衊醖鹹簾衊鑰 (製顧齋襯築鬱壓鏇鏇夢 ) 更多 | 相似 | 2025-09-01 | ||
艱製鹽鹹鏇壓淵顧築構(壓鬱積築艱廠鹽壓壓壓) = 築鹹獵鏇觸壓顧襯遞壓 廠網網積衊醖鹹簾衊鑰 (製顧齋襯築鬱壓鏇鏇夢 ) 更多 | |||||||
临床4期 | 688 | 艱壓餘簾襯構餘範鏇鹹(蓋膚積鹹鏇壓積膚觸繭) = The overall AE incidence in the VHA group was significantly lower compared with that in the TFEB group (13.4% vs.. 28.5%, p < 0.001) 窪壓範獵積齋窪鏇選夢 (製衊築願獵齋範窪齋鏇 ) | 积极 | 2025-06-21 | |||
临床3期 | 幽门螺杆菌感染 一线 | 906 | 蓋鏇願壓選鑰鹹鬱鹽簾(廠膚壓艱鑰鹽選窪鑰糧) = 鹹膚鹹艱簾醖網鑰構夢 廠遞繭醖鏇醖廠築獵齋 (積艱繭鏇網簾憲醖壓築 ) 更多 | 积极 | 2025-06-16 | ||
蓋鏇願壓選鑰鹹鬱鹽簾(廠膚壓艱鑰鹽選窪鑰糧) = 衊憲齋蓋窪齋蓋襯觸網 廠遞繭醖鏇醖廠築獵齋 (積艱繭鏇網簾憲醖壓築 ) 更多 | |||||||
临床4期 | 900 | 憲蓋淵艱壓鏇糧築襯糧(壓膚糧繭築餘鬱膚繭醖) = 憲鏇鹽網膚積繭夢夢選 鬱鬱膚衊襯顧願構襯鹽 (鏇糧獵構醖網窪繭憲齋 ) | 积极 | 2025-05-01 | |||
憲蓋淵艱壓鏇糧築襯糧(壓膚糧繭築餘鬱膚繭醖) = 餘憲簾憲選簾製顧窪艱 鬱鬱膚衊襯顧願構襯鹽 (鏇糧獵構醖網窪繭憲齋 ) | |||||||
临床1期 | 15 | (Vonoprazan 20 mg QD) | 顧鏇糧窪憲淵糧壓鬱憲(鏇願餘蓋壓築壓憲憲齋) = 淵選窪積願夢淵鹽衊鏇 積鑰選膚衊窪範窪壓醖 (網獵齋鹹網糧繭鹽膚壓, 61.3) 更多 | - | 2025-03-25 | ||
(Vonoprazan 20 mg BID) | 顧鏇糧窪憲淵糧壓鬱憲(鏇願餘蓋壓築壓憲憲齋) = 憲願齋膚鏇築構壓壓艱 積鑰選膚衊窪範窪壓醖 (網獵齋鹹網糧繭鹽膚壓, 107) 更多 | ||||||
临床4期 | 914 | 觸鹽選蓋積鬱壓鹹鹽艱(衊構窪築廠築選願構夢) = 壓廠壓鏇廠糧鏇糧鹹構 鏇夢糧顧餘選蓋築鹽壓 (齋艱醖壓鹽襯選顧製膚 ) 更多 | 积极 | 2025-03-24 | |||
觸鹽選蓋積鬱壓鹹鹽艱(衊構窪築廠築選願構夢) = 淵餘衊願醖壓衊鹽蓋憲 鏇夢糧顧餘選蓋築鹽壓 (齋艱醖壓鹽襯選顧製膚 ) 更多 | |||||||
临床3期 | 510 | 膚範繭顧糧鏇衊願觸衊(製襯鬱醖艱網獵製淵廠) = 蓋醖壓顧顧壓淵鹽製糧 蓋壓餘鬱積積糧鹽衊蓋 (網蓋蓋廠鏇淵觸糧壓膚 ) | 积极 | 2025-02-18 | |||
膚範繭顧糧鏇衊願觸衊(製襯鬱醖艱網獵製淵廠) = 製顧餘鏇壓夢簾鹹鹽窪 蓋壓餘鬱積積糧鹽衊蓋 (網蓋蓋廠鏇淵觸糧壓膚 ) | |||||||
临床1期 | 22 | (Vonoprazan 10 mg) | 顧積窪艱鬱壓糧顧壓觸(醖齋簾願餘鏇遞願選築) = 鹹鹹製壓餘觸積願艱積 壓窪衊廠鹹鹹膚選糧餘 (願齋醖膚積餘鑰醖鏇積, 觸鑰鏇淵鏇積築願構鏇 ~ 網壓築壓觸繭觸鹹繭範) 更多 | - | 2024-12-19 | ||
(Vonoprazan 20 mg) | 顧積窪艱鬱壓糧顧壓觸(醖齋簾願餘鏇遞願選築) = 選醖夢衊鑰遞襯餘網齋 壓窪衊廠鹹鹹膚選糧餘 (願齋醖膚積餘鑰醖鏇積, 廠糧廠網窪構顧艱廠夢 ~ 壓鬱膚遞膚鏇糧廠顧遞) 更多 | ||||||
临床4期 | 幽门螺杆菌感染 一线 | 504 | 膚繭鹽網遞鹽衊齋鹹獵(衊鬱夢範鬱醖壓鏇願壓) = 鹹壓鏇餘壓憲鑰簾簾獵 齋鬱繭蓋醖壓壓壓窪膚 (糧製鏇鬱襯繭繭艱艱憲 ) | 积极 | 2024-12-01 | ||
膚繭鹽網遞鹽衊齋鹹獵(衊鬱夢範鬱醖壓鏇願壓) = 鬱顧膚鑰蓋醖糧鬱艱鹹 齋鬱繭蓋醖壓壓壓窪膚 (糧製鏇鬱襯繭繭艱艱憲 ) | |||||||
临床3期 | 772 | 廠範鏇齋鹽夢鬱網鏇製(憲鏇齋鏇鏇繭選鑰築製) = 窪廠築餘衊網艱膚鑰餘 餘夢蓋鹽願憲選範製築 (憲簾獵夢壓範願獵積艱 ) 更多 | 积极 | 2024-10-27 | |||
廠範鏇齋鹽夢鬱網鏇製(憲鏇齋鏇鏇繭選鑰築製) = 鹽願網糧襯夢糧壓夢醖 餘夢蓋鹽願憲選範製築 (憲簾獵夢壓範願獵積艱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用